Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 24 entries
Sorted by: Best Match Show Resources per page
Novel allosteric ligands of the angiotensin receptor AT1R as autoantibody blockers.

Proceedings of the National Academy of Sciences of the United States of America

Singh KD, Jara ZP, Harford T, Saha PP, Pardhi TR, Desnoyer R, Karnik SS.
PMID: 34380734
Proc Natl Acad Sci U S A. 2021 Aug 17;118(33). doi: 10.1073/pnas.2019126118.

While orthosteric ligands of the angiotensin II (AngII) type 1 receptor (AT1R) are available for clinical and research applications, allosteric ligands are not known for this important G protein-coupled receptor (GPCR). Allosteric ligands are useful tools to modulate receptor...

Cite
Singh KD, Jara ZP, Harford T, et al. Novel allosteric ligands of the angiotensin receptor AT1R as autoantibody blockers. Proc Natl Acad Sci U S A. 2021;118(33)doi: 10.1073/pnas.2019126118.
Singh, K. D., Jara, Z. P., Harford, T., Saha, P. P., Pardhi, T. R., Desnoyer, R., & Karnik, S. S. (2021). Novel allosteric ligands of the angiotensin receptor AT1R as autoantibody blockers. Proceedings of the National Academy of Sciences of the United States of America, 118(33), . https://doi.org/10.1073/pnas.2019126118
Singh, Khuraijam Dhanachandra, et al. "Novel allosteric ligands of the angiotensin receptor AT1R as autoantibody blockers." Proceedings of the National Academy of Sciences of the United States of America vol. 118,33 (2021). doi: https://doi.org/10.1073/pnas.2019126118
Singh KD, Jara ZP, Harford T, Saha PP, Pardhi TR, Desnoyer R, Karnik SS. Novel allosteric ligands of the angiotensin receptor AT1R as autoantibody blockers. Proc Natl Acad Sci U S A. 2021 Aug 17;118(33). doi: 10.1073/pnas.2019126118. PMID: 34380734; PMCID: PMC8379978.
Copy Download .nbib Format: NLM
Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity.

Pharmacology research & perspectives

Higgins GA, Desnoyer J, Van Niekerk A, Silenieks LB, Lau W, Thevarkunnel S, Izhakova J, DeLannoy IA, Fletcher PJ, DeLay J, Dobson H.
PMID: 25692009
Pharmacol Res Perspect. 2015 Feb;3(1):e00084. doi: 10.1002/prp2.84. Epub 2014 Nov 07.

The 5-HT2C receptor agonist lorcaserin (Belviq®) has been Food and Drug Administration (FDA) approved for the treatment of obesity. The present study is a back translational investigation into the effect of 28-day lorcaserin treatment in a diet-induced obesity (DIO)...

Cite
Higgins GA, Desnoyer J, Van Niekerk A, et al. Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity. Pharmacol Res Perspect. 2014;3(1):e00084doi: 10.1002/prp2.84.
Higgins, G. A., Desnoyer, J., Van Niekerk, A., Silenieks, L. B., Lau, W., Thevarkunnel, S., Izhakova, J., DeLannoy, I. A., Fletcher, P. J., DeLay, J., & Dobson, H. (2015). Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity. Pharmacology research & perspectives, 3(1), e00084. https://doi.org/10.1002/prp2.84
Higgins, Guy A, et al. "Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity." Pharmacology research & perspectives vol. 3,1 (2015): e00084. doi: https://doi.org/10.1002/prp2.84
Higgins GA, Desnoyer J, Van Niekerk A, Silenieks LB, Lau W, Thevarkunnel S, Izhakova J, DeLannoy IA, Fletcher PJ, DeLay J, Dobson H. Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity. Pharmacol Res Perspect. 2015 Feb;3(1):e00084. doi: 10.1002/prp2.84. Epub 2014 Nov 07. PMID: 25692009; PMCID: PMC4317222.
Copy Download .nbib Format: NLM
Effect of concentrate percentage on ruminal pH and time-budget in dairy goats.

Animal : an international journal of animal bioscience

Desnoyers M, Duvaux-Ponter C, Rigalma K, Roussel S, Martin O, Giger-Reverdin S.
PMID: 22444087
Animal. 2008 Dec;2(12):1802-8. doi: 10.1017/S1751731108003157.

The aim of this study was to compare rumen pH and time-budget in eight mid-lactation goats receiving two diets in a cross-over design (low-concentrate diet (L): 30% and high-concentrate diet (H): 60% concentrate). Feeding H increased daily intake (4.3...

Cite
Desnoyers M, Duvaux-Ponter C, Rigalma K, et al. Effect of concentrate percentage on ruminal pH and time-budget in dairy goats. Animal. 2008;2(12):1802-8doi: 10.1017/S1751731108003157.
Desnoyers, M., Duvaux-Ponter, C., Rigalma, K., Roussel, S., Martin, O., & Giger-Reverdin, S. (2008). Effect of concentrate percentage on ruminal pH and time-budget in dairy goats. Animal : an international journal of animal bioscience, 2(12), 1802-8. https://doi.org/10.1017/S1751731108003157
Desnoyers, M, et al. "Effect of concentrate percentage on ruminal pH and time-budget in dairy goats." Animal : an international journal of animal bioscience vol. 2,12 (2008): 1802-8. doi: https://doi.org/10.1017/S1751731108003157
Desnoyers M, Duvaux-Ponter C, Rigalma K, Roussel S, Martin O, Giger-Reverdin S. Effect of concentrate percentage on ruminal pH and time-budget in dairy goats. Animal. 2008 Dec;2(12):1802-8. doi: 10.1017/S1751731108003157. PMID: 22444087.
Copy Download .nbib Format: NLM
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer.

Cancers

Duchemann B, Remon J, Naigeon M, Mezquita L, Ferrara R, Cassard L, Jouniaux JM, Boselli L, Grivel J, Auclin E, Desnoyer A, Besse B, Chaput N.
PMID: 33287347
Cancers (Basel). 2020 Dec 03;12(12). doi: 10.3390/cancers12123625.

Immune checkpoint inhibitors are now a cornerstone of treatment for non-small cell lung cancer (NSCLC). Tissue-based assays, such as Programmed cell death protein 1 (PD-L1) expression or mismatch repair deficiency/microsatellite instability (MMRD/MSI) status, are approved as treatment drivers in...

Cite
Duchemann B, Remon J, Naigeon M, et al. Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. Cancers (Basel). 2020;12(12)doi: 10.3390/cancers12123625.
Duchemann, B., Remon, J., Naigeon, M., Mezquita, L., Ferrara, R., Cassard, L., Jouniaux, J. M., Boselli, L., Grivel, J., Auclin, E., Desnoyer, A., Besse, B., & Chaput, N. (2020). Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. Cancers, 12(12), . https://doi.org/10.3390/cancers12123625
Duchemann, Boris, et al. "Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer." Cancers vol. 12,12 (2020). doi: https://doi.org/10.3390/cancers12123625
Duchemann B, Remon J, Naigeon M, Mezquita L, Ferrara R, Cassard L, Jouniaux JM, Boselli L, Grivel J, Auclin E, Desnoyer A, Besse B, Chaput N. Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. Cancers (Basel). 2020 Dec 03;12(12). doi: 10.3390/cancers12123625. PMID: 33287347; PMCID: PMC7761725.
Copy Download .nbib Format: NLM
Designing .

Insects

Staunton KM, Liu J, Townsend M, Desnoyer M, Howell P, Crawford JE, Xiang W, Snoad N, Burkot TR, Ritchie SA.
PMID: 33925425
Insects. 2021 Apr 27;12(5). doi: 10.3390/insects12050388.

Effective surveillance of

Cite
Staunton KM, Liu J, Townsend M, et al. Designing . Insects. 2021;12(5)doi: 10.3390/insects12050388.
Staunton, K. M., Liu, J., Townsend, M., Desnoyer, M., Howell, P., Crawford, J. E., Xiang, W., Snoad, N., Burkot, T. R., & Ritchie, S. A. (2021). Designing . Insects, 12(5), . https://doi.org/10.3390/insects12050388
Staunton, Kyran M, et al. "Designing ." Insects vol. 12,5 (2021). doi: https://doi.org/10.3390/insects12050388
Staunton KM, Liu J, Townsend M, Desnoyer M, Howell P, Crawford JE, Xiang W, Snoad N, Burkot TR, Ritchie SA. Designing . Insects. 2021 Apr 27;12(5). doi: 10.3390/insects12050388. PMID: 33925425; PMCID: PMC8146609.
Copy Download .nbib Format: NLM
Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials.

Journal of the National Comprehensive Cancer Network : JNCCN

Wilson BE, Nadler MB, Desnoyers A, Amir E.
PMID: 34479210
J Natl Compr Canc Netw. 2021 Sep 03;1-8. doi: 10.6004/jnccn.2021.7015. Epub 2021 Sep 03.

BACKGROUND: Censoring due to early drug discontinuation (EDD) or withdrawal of consent or loss to follow-up (WCLFU) can result in postrandomization bias. In oncology, censoring rules vary with no defined standards. In this study, we sought to describe the...

Cite
Wilson BE, Nadler MB, Desnoyers A, et al. Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials. J Natl Compr Canc Netw. 2021;1-8doi: 10.6004/jnccn.2021.7015.
Wilson, B. E., Nadler, M. B., Desnoyers, A., & Amir, E. (2021). Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials. Journal of the National Comprehensive Cancer Network : JNCCN, 1-8. https://doi.org/10.6004/jnccn.2021.7015
Wilson, Brooke E, et al. "Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials." Journal of the National Comprehensive Cancer Network : JNCCN vol. (2021): 1-8. doi: https://doi.org/10.6004/jnccn.2021.7015
Wilson BE, Nadler MB, Desnoyers A, Amir E. Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials. J Natl Compr Canc Netw. 2021 Sep 03;1-8. doi: 10.6004/jnccn.2021.7015. Epub 2021 Sep 03. PMID: 34479210.
Copy Download .nbib Format: NLM
Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers.

Journal of Cancer

Al-Showbaki L, Nadler MB, Desnoyers A, Almugbel FA, Cescon DW, Amir E.
PMID: 34093837
J Cancer. 2021 May 19;12(14):4372-4378. doi: 10.7150/jca.57413. eCollection 2021.

No abstract available.

Cite
Al-Showbaki L, Nadler MB, Desnoyers A, et al. Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers. J Cancer. 2021;12(14):4372-4378doi: 10.7150/jca.57413.
Al-Showbaki, L., Nadler, M. B., Desnoyers, A., Almugbel, F. A., Cescon, D. W., & Amir, E. (2021). Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers. Journal of Cancer, 12(14), 4372-4378. https://doi.org/10.7150/jca.57413
Al-Showbaki, Laith, et al. "Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers." Journal of Cancer vol. 12,14 (2021): 4372-4378. doi: https://doi.org/10.7150/jca.57413
Al-Showbaki L, Nadler MB, Desnoyers A, Almugbel FA, Cescon DW, Amir E. Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers. J Cancer. 2021 May 19;12(14):4372-4378. doi: 10.7150/jca.57413. eCollection 2021. PMID: 34093837; PMCID: PMC8176414.
Copy Download .nbib Format: NLM
Predictive Model for the Calculation of Interfacial Tension in Nonideal Electrolytic Systems.

Journal of colloid and interface science

Desnoyer C, Masbernat O, Gourdon C.
PMID: 9241200
J Colloid Interface Sci. 1997 Jul 01;191(1):22-9. doi: 10.1006/jcis.1997.4917.

A new model is proposed for the calculation of the interfacial tension between an organic solvent and concentrated aqueous solutions of electrolytes. The interfacial tension is derived from the isothermal Gibbs equation. The increase or decrease of interfacial tension...

Cite
Desnoyer C, Masbernat O, Gourdon C. Predictive Model for the Calculation of Interfacial Tension in Nonideal Electrolytic Systems. J Colloid Interface Sci. 1997;191(1):22-9doi: 10.1006/jcis.1997.4917.
Desnoyer, C., Masbernat, O., & Gourdon, C. (1997). Predictive Model for the Calculation of Interfacial Tension in Nonideal Electrolytic Systems. Journal of colloid and interface science, 191(1), 22-9. https://doi.org/10.1006/jcis.1997.4917
Desnoyer, et al. "Predictive Model for the Calculation of Interfacial Tension in Nonideal Electrolytic Systems." Journal of colloid and interface science vol. 191,1 (1997): 22-9. doi: https://doi.org/10.1006/jcis.1997.4917
Desnoyer C, Masbernat O, Gourdon C. Predictive Model for the Calculation of Interfacial Tension in Nonideal Electrolytic Systems. J Colloid Interface Sci. 1997 Jul 01;191(1):22-9. doi: 10.1006/jcis.1997.4917. PMID: 9241200.
Copy Download .nbib Format: NLM
The Canadian Institutes of Health Research response to antimicrobial resistance.

Canada communicable disease report = Releve des maladies transmissibles au Canada

Pagé EL, Desnoyers S, Létourneau IJ, Keown K, Jackson A, Ouellette M.
PMID: 29769970
Can Commun Dis Rep. 2015 Nov 19;41:11-15. doi: 10.14745/ccdr.v41is5a03. eCollection 2015 Nov 19.

Antimicrobial resistance (AMR) has been a research priority for the Canadian Institutes of Health Research (CIHR), Institute of Infection and Immunity (III) since its inception, and a number of strategic research initiatives have been launched to address this global...

Cite
Pagé EL, Desnoyers S, Létourneau IJ, et al. The Canadian Institutes of Health Research response to antimicrobial resistance. Can Commun Dis Rep. 2015;41:11-15doi: 10.14745/ccdr.v41is5a03.
Pagé, E. L., Desnoyers, S., Létourneau, I. J., Keown, K., Jackson, A., & Ouellette, M. (2015). The Canadian Institutes of Health Research response to antimicrobial resistance. Canada communicable disease report = Releve des maladies transmissibles au Canada, 4111-15. https://doi.org/10.14745/ccdr.v41is5a03
Pagé, E L, et al. "The Canadian Institutes of Health Research response to antimicrobial resistance." Canada communicable disease report = Releve des maladies transmissibles au Canada vol. 41 (2015): 11-15. doi: https://doi.org/10.14745/ccdr.v41is5a03
Pagé EL, Desnoyers S, Létourneau IJ, Keown K, Jackson A, Ouellette M. The Canadian Institutes of Health Research response to antimicrobial resistance. Can Commun Dis Rep. 2015 Nov 19;41:11-15. doi: 10.14745/ccdr.v41is5a03. eCollection 2015 Nov 19. PMID: 29769970; PMCID: PMC5868538.
Copy Download .nbib Format: NLM
BST-CarGel® Treatment Maintains Cartilage Repair Superiority over Microfracture at 5 Years in a Multicenter Randomized Controlled Trial.

Cartilage

Shive MS, Stanish WD, McCormack R, Forriol F, Mohtadi N, Pelet S, Desnoyers J, Méthot S, Vehik K, Restrepo A.
PMID: 26069709
Cartilage. 2015 Apr;6(2):62-72. doi: 10.1177/1947603514562064.

OBJECTIVE: The efficacy and safety of BST-CarGel®, a chitosan scaffold for cartilage repair was compared with microfracture alone at 1 year during a multicenter randomized controlled trial in the knee. This report was undertaken to investigate 5-year structural and...

Cite
Shive MS, Stanish WD, McCormack R, et al. BST-CarGel® Treatment Maintains Cartilage Repair Superiority over Microfracture at 5 Years in a Multicenter Randomized Controlled Trial. Cartilage. 2015;6(2):62-72doi: 10.1177/1947603514562064.
Shive, M. S., Stanish, W. D., McCormack, R., Forriol, F., Mohtadi, N., Pelet, S., Desnoyers, J., Méthot, S., Vehik, K., & Restrepo, A. (2015). BST-CarGel® Treatment Maintains Cartilage Repair Superiority over Microfracture at 5 Years in a Multicenter Randomized Controlled Trial. Cartilage, 6(2), 62-72. https://doi.org/10.1177/1947603514562064
Shive, Matthew S, et al. "BST-CarGel® Treatment Maintains Cartilage Repair Superiority over Microfracture at 5 Years in a Multicenter Randomized Controlled Trial." Cartilage vol. 6,2 (2015): 62-72. doi: https://doi.org/10.1177/1947603514562064
Shive MS, Stanish WD, McCormack R, Forriol F, Mohtadi N, Pelet S, Desnoyers J, Méthot S, Vehik K, Restrepo A. BST-CarGel® Treatment Maintains Cartilage Repair Superiority over Microfracture at 5 Years in a Multicenter Randomized Controlled Trial. Cartilage. 2015 Apr;6(2):62-72. doi: 10.1177/1947603514562064. PMID: 26069709; PMCID: PMC4462252.
Copy Download .nbib Format: NLM
Correction: Interaction of G-Protein βγ Complex with Chromatin Modulates GPCR-Dependent Gene Regulation.

PloS one

Bhatnagar A, Unal H, Jagannathan R, Kaveti S, Duan ZH, Yong S, Vasanji A, Kinter M, Desnoyer R, Karnik SS.
PMID: 27144543
PLoS One. 2016 May 04;11(5):e0155198. doi: 10.1371/journal.pone.0155198. eCollection 2016.

[This corrects the article DOI: 10.1371/journal.pone.0052689.].

Cite
Bhatnagar A, Unal H, Jagannathan R, et al. Correction: Interaction of G-Protein βγ Complex with Chromatin Modulates GPCR-Dependent Gene Regulation. PLoS One. 2016;11(5):e0155198doi: 10.1371/journal.pone.0155198.
Bhatnagar, A., Unal, H., Jagannathan, R., Kaveti, S., Duan, Z. H., Yong, S., Vasanji, A., Kinter, M., Desnoyer, R., & Karnik, S. S. (2016). Correction: Interaction of G-Protein βγ Complex with Chromatin Modulates GPCR-Dependent Gene Regulation. PloS one, 11(5), e0155198. https://doi.org/10.1371/journal.pone.0155198
Bhatnagar, Anushree, et al. "Correction: Interaction of G-Protein βγ Complex with Chromatin Modulates GPCR-Dependent Gene Regulation." PloS one vol. 11,5 (2016): e0155198. doi: https://doi.org/10.1371/journal.pone.0155198
Bhatnagar A, Unal H, Jagannathan R, Kaveti S, Duan ZH, Yong S, Vasanji A, Kinter M, Desnoyer R, Karnik SS. Correction: Interaction of G-Protein βγ Complex with Chromatin Modulates GPCR-Dependent Gene Regulation. PLoS One. 2016 May 04;11(5):e0155198. doi: 10.1371/journal.pone.0155198. eCollection 2016. PMID: 27144543; PMCID: PMC4856381.
Copy Download .nbib Format: NLM
Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials.

Journal of the National Comprehensive Cancer Network : JNCCN

Wilson BE, Nadler MB, Desnoyers A, Amir E.
PMID: 34479210
J Natl Compr Canc Netw. 2021 Sep 03;19(12):1433-1440. doi: 10.6004/jnccn.2021.7015.

BACKGROUND: Censoring due to early drug discontinuation (EDD) or withdrawal of consent or loss to follow-up (WCLFU) can result in postrandomization bias. In oncology, censoring rules vary with no defined standards. In this study, we sought to describe the...

Cite
Wilson BE, Nadler MB, Desnoyers A, et al. Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials. J Natl Compr Canc Netw. 2021;19(12):1433-1440doi: 10.6004/jnccn.2021.7015.
Wilson, B. E., Nadler, M. B., Desnoyers, A., & Amir, E. (2021). Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials. Journal of the National Comprehensive Cancer Network : JNCCN, 19(12), 1433-1440. https://doi.org/10.6004/jnccn.2021.7015
Wilson, Brooke E, et al. "Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials." Journal of the National Comprehensive Cancer Network : JNCCN vol. 19,12 (2021): 1433-1440. doi: https://doi.org/10.6004/jnccn.2021.7015
Wilson BE, Nadler MB, Desnoyers A, Amir E. Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials. J Natl Compr Canc Netw. 2021 Sep 03;19(12):1433-1440. doi: 10.6004/jnccn.2021.7015. PMID: 34479210.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 24 entries